Dear SMA Community,

We are pleased to share a new format for Biogen’s ongoing updates for the community. We hope this layout allows you to more easily find updates and information related to Biogen’s clinical research, community outreach and SPINRAZA® (nusinersen) programs. We look forward to hearing your feedback as well.

The upcoming 2021 Virtual SMA Conference organized by Cure SMA is always a highlight for our team. We are excited to connect with the SMA community at our virtual booth and during our live Family Symposium. Also, we look forward to sharing updates and outcomes from exciting research with healthcare providers and researchers through several posters and talks at the 2021 Virtual SMA Research & Clinical Care Meeting.

– The Biogen Team

PUBLICATIONS AND DATA UPDATES

Earlier this year, Biogen presented new data from the SPINRAZA clinical development program at the American Academy of Neurology (AAN) annual meeting.

➢ Key highlights included results reinforcing the potential of neurofilament levels as a biomarker for treatment response in SMA. Researchers analyzed blood samples collected from 75 people with SMA enrolled in the CHERISH/SHINE studies.¹

➢ The use of biomarkers could improve the understanding of disease mechanisms and interventions for SMA and other diseases. Biogen has included the measurement as an exploratory endpoint in its DEVOTE and RESPOND studies.

Earlier this year, researchers from Stanford University published a paper in Neurology Clinical Practice titled, Nusinersen Treatment in Adults with Spinal Muscular Atrophy.² This paper adds important new information to the already substantial body of independent, observational studies (real-world evidence) describing clinical outcomes of SPINRAZA use in adults with SMA as reported in at least 10 other publications.³⁻¹²

INDICATION

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines.

Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Please see Important Safety Information continued on page 2 and click here to access full Prescribing Information.

SPZ-US-4270 06/21

www.biogen.com | 781-464-3260 | patientadvocacy@biogen.com ©2021 Biogen. All Rights Reserved.


